Clinical trials: Non-squamous NSCLC
Non-Small Cell Lung Cancer
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
The optimal treatment for Stage I or Stage IIA non-small cell lung cancer (NSCLC) remains controversial. Radiographic surveillance alone has been recommended for stage I and stage IIA patients after the tumor is removed…
- Trial name
- NCT01817192
- Testing
- Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
- Where
- 49 sites in United States, France and 1 more
- Volunteers
- 420 people
- Sponsor
- Razor Genomics
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
This 2 arm study will assess the efficacy and safety of Tarceva plus gemcitabine, compared with gemcitabine alone, in the treatment of chemotherapy-naive patients with advanced non-small cell lung cancer.
- Trial name
- NCT00518011
- Testing
- Erlotinib, Gemcitabine
- Where
- 14 sites in Australia
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, Non Small Cell Lung Cancer
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355.
- Conditions
- Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT01059643
- Testing
- LY2523355, pegfilgrastim
- Where
- 18 sites in United States
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Non-Squamous Non-Small Cell Lung Cancer
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
This open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small cell lung cancer.
- Trial name
- NCT00961415
- Testing
- bevacizumab [Avastin], cisplatin, pemetrexed
- Where
- 91 sites in France, Germany and 10 more
- Volunteers
- 376 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Non Squamous, Non-small-cell Lung Cancer
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
This study is to determine if the combination regimen of tivantinib with erlotinib will improve overall survival relative to erlotinib alone in subjects with locally advanced or metastatic non-squamous, non-small cell lung cancer…
- Trial name
- NCT01244191
- Testing
- Tivantinib, Erlotinib
- Where
- 304 sites in United States, Argentina and 21 more
- Volunteers
- 1,048 people
- Sponsor
- Daiichi Sankyo
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
The primary objective of this trial is to demonstrate pharmacokinetic (PK) similarity of ABP 234 compared with the pembrolizumab reference product (Keytruda®).
- Trial name
- NCT06311721
- Testing
- ABP 234, Pembrolizumab (US), Pembrolizumab (EU)
- Where
- 218 sites in United States, Argentina and 21 more
- Volunteers
- 315 people
- Sponsor
- Amgen
Non-Squamous Non-Small Cell Lung Cancer
Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants
The purpose of this non-interventional study is the collection and documentation of data on safety and efficacy of intravenous (IV) bevacizumab (Avastin) in addition to platinum-based chemotherapy for first-line treatment in…
- Trial name
- NCT02596958
- Testing
- Bevacizumab
- Where
- Germany
- Volunteers
- 996 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer
In this study researchers want to gather relevant information regarding the safety of BAY2416964 and how well the drug works in participants with a type of solid tumors that cannot be cured by currently available drugs.
- Trial name
- NCT04069026
- Testing
- BAY2416964
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 78 people
- Sponsor
- Bayer
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer
A Study of VET3-TGI in Patients With Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by…
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- STEALTH-001 (NCT06444815)
- Testing
- VET3-TGI, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- KaliVir Immunotherapeutics
Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
This randomized, open-label study was designed to evaluate and compare the safety and efficacy of atezolizumab with gemcitabine + cisplatin or carboplatin in PD-L1 selected participants with chemotherapy-naive, Stage IV squamous…
- Trial name
- NCT02409355
- Testing
- Atezolizumab, Carboplatin, Cisplatin
- Where
- 82 sites in United States, Czechia and 12 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Non-small Cell Lung Cancer
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
The purpose of the study is to assess the objective response rate (change in tumor size from baseline) in patients with advanced or metastatic squamous cell nonsmall-cell lung cancer treated with Nivolumab (BMS-936558) after…
- Trial name
- NCT01721759
- Testing
- Nivolumab
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 117 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Non Small Cell Lung Cancer
A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer
The purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01005680
- Testing
- Pemetrexed, Gemcitabine, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 256 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
This is a randomized, open-label, multicenter, phase 3 clinical study comparing the efficacy and safety of SHR-A1811 in combination with Adebrelimab versus platinum-based doublet chemotherapy in combination with Tislelizumab as…
- Trial name
- NCT07896005
- Testing
- SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection
- Where
- 2 sites in China
- Volunteers
- 436 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Melanoma, Non-small Cell Lung Cancer
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R).
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT02452424
- Testing
- PLX3397, Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 78 people
- Sponsor
- Daiichi Sankyo
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.